Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist

Diabet Med. 2017 Dec;34(12):1792-1794. doi: 10.1111/dme.13527.

Abstract

Background: Familial partial lipodystrophies are rare monogenic disorders that are often associated with diabetes. In such cases, it can be difficult to achieve glycaemic control.

Case report: We report a 34-year old woman with familial partial lipodystrophy type 2 (Dunnigan) and diabetes; her hyperglycaemia persisted despite metformin treatment. A combined intravenous glucose tolerance-euglycaemic clamp test showed severe insulin resistance, as expected, but also showed strongly diminished first-phase insulin secretion. After the latter finding, we added the glucagon-like peptide-1 receptor agonist liraglutide to the patient's treatment regimen, which rapidly normalized plasma glucose levels. HbA1c values <42 mmol/mol (6.0%) have now been maintained for over 4 years.

Conclusion: This case suggests that a glucagon-like peptide-1 receptor agonist may be a useful component of glucose-lowering therapy in individuals with familial partial lipodystrophy and diabetes mellitus.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Follow-Up Studies
  • Glucagon-Like Peptide-1 Receptor / agonists*
  • Humans
  • Insulin / metabolism*
  • Insulin Resistance
  • Insulin Secretion
  • Lipodystrophy, Familial Partial / drug therapy*
  • Lipodystrophy, Familial Partial / metabolism
  • Liraglutide / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Insulin
  • Liraglutide